Enterovirus A71 Vaccines

Enterovirus A71 (EV-A71) is a major causative agent of hand, foot, and mouth disease (HFMD) and herpangina. Moreover, EV-A71 infection can lead to neurological complications and death. Vaccination is the most efficient way to control virus infection. There are currently three inactivated, whole EV-A...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mei-Ling, Shih, Shin-Ru, Tolbert, Blanton S., Brewer, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997495/
https://www.ncbi.nlm.nih.gov/pubmed/33673595
http://dx.doi.org/10.3390/vaccines9030199
_version_ 1783670342267437056
author Li, Mei-Ling
Shih, Shin-Ru
Tolbert, Blanton S.
Brewer, Gary
author_facet Li, Mei-Ling
Shih, Shin-Ru
Tolbert, Blanton S.
Brewer, Gary
author_sort Li, Mei-Ling
collection PubMed
description Enterovirus A71 (EV-A71) is a major causative agent of hand, foot, and mouth disease (HFMD) and herpangina. Moreover, EV-A71 infection can lead to neurological complications and death. Vaccination is the most efficient way to control virus infection. There are currently three inactivated, whole EV-A71 vaccines licensed by the China NMPA (National Medical Products Administration). Several other types of vaccines, such as virus-like particles and recombinant VP1 (capsid protein), are also under development. In this review, we discuss recent advances in the development of EV-A71 vaccines.
format Online
Article
Text
id pubmed-7997495
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79974952021-03-27 Enterovirus A71 Vaccines Li, Mei-Ling Shih, Shin-Ru Tolbert, Blanton S. Brewer, Gary Vaccines (Basel) Review Enterovirus A71 (EV-A71) is a major causative agent of hand, foot, and mouth disease (HFMD) and herpangina. Moreover, EV-A71 infection can lead to neurological complications and death. Vaccination is the most efficient way to control virus infection. There are currently three inactivated, whole EV-A71 vaccines licensed by the China NMPA (National Medical Products Administration). Several other types of vaccines, such as virus-like particles and recombinant VP1 (capsid protein), are also under development. In this review, we discuss recent advances in the development of EV-A71 vaccines. MDPI 2021-02-27 /pmc/articles/PMC7997495/ /pubmed/33673595 http://dx.doi.org/10.3390/vaccines9030199 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Review
Li, Mei-Ling
Shih, Shin-Ru
Tolbert, Blanton S.
Brewer, Gary
Enterovirus A71 Vaccines
title Enterovirus A71 Vaccines
title_full Enterovirus A71 Vaccines
title_fullStr Enterovirus A71 Vaccines
title_full_unstemmed Enterovirus A71 Vaccines
title_short Enterovirus A71 Vaccines
title_sort enterovirus a71 vaccines
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997495/
https://www.ncbi.nlm.nih.gov/pubmed/33673595
http://dx.doi.org/10.3390/vaccines9030199
work_keys_str_mv AT limeiling enterovirusa71vaccines
AT shihshinru enterovirusa71vaccines
AT tolbertblantons enterovirusa71vaccines
AT brewergary enterovirusa71vaccines

Ejemplares similares